Jamadagni Sameer, Pandkar Prasad, Saundankar Tushar, Shirke Girish, Malekar Shailesh, Vaidya V G
Shri Vishwavati Ayurvedic Chikitsalay and Research Centre, Kolhapur, Maharashtra, India.
Bharati Vidyapeeth Deemed University, College of Ayurved, Pune, Maharashtra, India.
J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100590. doi: 10.1016/j.jaim.2022.100590. Epub 2022 May 24.
Apart from all the gloominess, the COVID-19 Pandemic has a silver lining of bringing a renaissance as Ayurveda and integrated medicine are becoming a choice for acute as well as infective diseases. Here we report outcomes of a preliminary work, the randomized controlled trial (CTRI/2021/02/031256) of Madhav Rasayan Plus, an Ayurveda formulation as adjuvant in moderate COVID-19 patients. Madhav Rasayan Plus is a herbomineral formulation beneficial for respiratory, coagulative and other systemic complements of COVID-19. Forty patients with moderate COVID-19 disease were included in two parallel groups (n = 20/group). The Intervention group (Treatment) received Madhav Rasayan Plus tablets (250 mg) twice a day for 15 days, along with standard care (SOC), while the control group received SOC alone. The intervention group significantly improved symptoms of COVID-19 like cough, breathlessness, fatigue and gastric disturbances. There was also statistically significant reduction in inflammatory markers like CRP and Ferritin. Tissue level markers like creatinine phosphokinase and NT- Pro BNP were found restored after treatment. The requirement of supplemental oxygen in the control group (6 days) was reduced by 2.5 times compared to the intervention group (2.4 days). There was also reduced hospital stay and reduced requirement of ICU in comparison with the control group. Also, the indices of fatigue severity score, disturbed sleep cycle score and quality of life revealed better and holistic recovery in the intervention group. This study reveals that COVID-19 and such infective diseases with vital complications can be better dealt with integrated management as immunomodulation and protection of tissues and vital organs are strengths of Ayurveda.
抛开所有的阴霾不谈，新冠疫情也有一线希望，即随着阿育吠陀医学和整合医学正成为治疗急性病和传染病的选择，迎来了一场复兴。在此，我们报告一项初步工作的结果，即一项关于Madhav Rasayan Plus（一种阿育吠陀配方药物，作为中度新冠肺炎患者的辅助用药）的随机对照试验（CTRI/2021/02/031256）。Madhav Rasayan Plus是一种草药矿物配方药物，对新冠肺炎的呼吸系统、凝血系统及其他全身状况有益。40例中度新冠肺炎患者被纳入两个平行组（每组n = 20）。干预组（治疗组）每天服用两次Madhav Rasayan Plus片剂（250毫克），持续15天，同时接受标准护理（SOC），而对照组仅接受标准护理。干预组显著改善了新冠肺炎的症状，如咳嗽、呼吸急促、疲劳和胃部不适。炎症标志物如CRP和铁蛋白也有统计学意义的降低。治疗后发现组织水平标志物如肌酸磷酸激酶和NT - Pro BNP恢复正常。对照组（6天）补充氧气的需求与干预组（2.4天）相比减少了2.5倍。与对照组相比，住院时间也缩短了，重症监护病房的需求也减少了。此外，疲劳严重程度评分、睡眠周期紊乱评分和生活质量指数显示，干预组的恢复更好且更全面。这项研究表明，对于新冠肺炎以及此类伴有严重并发症的传染病，通过整合管理可以更好地应对，因为免疫调节以及组织和重要器官的保护是阿育吠陀医学的优势。
